Final results of the BP22333 study demonstrate non-inferior pharmacokinetics and safety of subcutaneous administration of rituximab compared with intravenous administration as maintenance therapy in patients with follicular lymphoma - Salar, A; Avivi, I; Larouche, J F (Blood, 2012)
(Abstract 1641)